AU2014334563A1 - Methods for treating Chronic Obstructive Pulmonary disease using benralizumab - Google Patents

Methods for treating Chronic Obstructive Pulmonary disease using benralizumab Download PDF

Info

Publication number
AU2014334563A1
AU2014334563A1 AU2014334563A AU2014334563A AU2014334563A1 AU 2014334563 A1 AU2014334563 A1 AU 2014334563A1 AU 2014334563 A AU2014334563 A AU 2014334563A AU 2014334563 A AU2014334563 A AU 2014334563A AU 2014334563 A1 AU2014334563 A1 AU 2014334563A1
Authority
AU
Australia
Prior art keywords
patient
copd
benralizumab
antigen
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014334563A
Other languages
English (en)
Inventor
Ubaldo Martin
Lorin Roskos
Rene Van Der Merwe
Bing Wang
Christine Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2014334563A1 publication Critical patent/AU2014334563A1/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Request for Assignment Assignors: MEDIMMUNE, LLC.
Priority to AU2020202333A priority Critical patent/AU2020202333A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014334563A 2013-10-15 2014-10-14 Methods for treating Chronic Obstructive Pulmonary disease using benralizumab Abandoned AU2014334563A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020202333A AU2020202333A1 (en) 2013-10-15 2020-04-02 Methods for treating chronic obstructive pulmonary disease using benralizumab

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361891175P 2013-10-15 2013-10-15
US61/891,175 2013-10-15
US201461970126P 2014-03-25 2014-03-25
US61/970,126 2014-03-25
PCT/US2014/060432 WO2015057668A1 (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020202333A Division AU2020202333A1 (en) 2013-10-15 2020-04-02 Methods for treating chronic obstructive pulmonary disease using benralizumab

Publications (1)

Publication Number Publication Date
AU2014334563A1 true AU2014334563A1 (en) 2016-04-07

Family

ID=52809872

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014334563A Abandoned AU2014334563A1 (en) 2013-10-15 2014-10-14 Methods for treating Chronic Obstructive Pulmonary disease using benralizumab
AU2020202333A Abandoned AU2020202333A1 (en) 2013-10-15 2020-04-02 Methods for treating chronic obstructive pulmonary disease using benralizumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020202333A Abandoned AU2020202333A1 (en) 2013-10-15 2020-04-02 Methods for treating chronic obstructive pulmonary disease using benralizumab

Country Status (12)

Country Link
US (4) US20150104447A1 (enExample)
EP (2) EP3485902A1 (enExample)
JP (3) JP2016534996A (enExample)
KR (1) KR20160061352A (enExample)
CN (2) CN105636607A (enExample)
AU (2) AU2014334563A1 (enExample)
BR (1) BR112016008082A2 (enExample)
CA (1) CA2925402A1 (enExample)
MX (2) MX2016004329A (enExample)
RU (1) RU2706729C2 (enExample)
SG (2) SG11201601807XA (enExample)
WO (1) WO2015057668A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160068613A1 (en) 2013-04-29 2016-03-10 Hoffmann-La Roche Inc. Fc-receptor binding modified asymmetric antibodies and methods of use
MX380658B (es) 2014-01-15 2025-03-11 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
US10479836B2 (en) 2015-06-01 2019-11-19 National University Corporation University Of Toyama Method for treating pulmonary hypertension with interleukin-5 receptor antibody
CN109544378B (zh) * 2018-10-27 2024-06-25 平安医疗健康管理股份有限公司 一种肺源性心脏病资质认证方法、设备及服务器
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
MX2022006812A (es) * 2019-12-06 2022-08-25 Sanofi Biotechnology Metodos para tratar epoc mediante la administracion de un antagonista de il-33.
EP3957308A1 (en) 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
CA3223191A1 (en) * 2021-09-03 2023-03-09 University Of Utah Research Foundation Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
AU3672800A (en) * 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
WO2001060405A1 (en) * 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
ES2558689T3 (es) * 2007-05-14 2016-02-08 Medimmune, Llc Métodos para reducir los niveles de eosinófilos
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物
PL2627673T3 (pl) * 2010-10-15 2018-01-31 Medimmune Ltd Terapie poprawiające funkcje płuc
WO2012083132A2 (en) * 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
EP2710370A4 (en) * 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
CA2853858A1 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
SG11201600484TA (en) * 2013-08-12 2016-02-26 Medimmune Llc Methods for improving asthma symptoms using benralizumab
DK3033104T3 (da) * 2013-08-12 2019-06-17 Astrazeneca Ab Fremgangsmåder til forøgelse af forceret eksspiratorisk volumen hos astmatikere ved anvendelse af benralizumab
CN105451760A (zh) * 2013-08-12 2016-03-30 米迪缪尼有限公司 使用贝那利珠单抗降低哮喘恶化率的方法

Also Published As

Publication number Publication date
MX2019013468A (es) 2020-02-12
JP6870037B2 (ja) 2021-05-12
EP3057609A4 (en) 2017-03-22
SG10201807318RA (en) 2018-09-27
CN105636607A (zh) 2016-06-01
WO2015057668A1 (en) 2015-04-23
JP2019203009A (ja) 2019-11-28
CA2925402A1 (en) 2015-04-23
CN113230399A (zh) 2021-08-10
KR20160061352A (ko) 2016-05-31
EP3057609A1 (en) 2016-08-24
JP2021107421A (ja) 2021-07-29
US20200123262A1 (en) 2020-04-23
JP2016534996A (ja) 2016-11-10
AU2020202333A1 (en) 2020-04-23
US20170107291A1 (en) 2017-04-20
MX2016004329A (es) 2016-11-10
BR112016008082A2 (pt) 2017-10-17
RU2706729C2 (ru) 2019-11-20
US20180291108A1 (en) 2018-10-11
EP3485902A1 (en) 2019-05-22
RU2016118425A (ru) 2017-11-21
SG11201601807XA (en) 2016-04-28
US20150104447A1 (en) 2015-04-16
RU2016118425A3 (enExample) 2018-07-19

Similar Documents

Publication Publication Date Title
US20200123262A1 (en) Methods For Treating Chronic Obstructive Pulmonary Disease Using Benralizumab
EA034864B1 (ru) Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой
US20240409626A1 (en) Methods for treating chronic obstructive pulmonary disease in an enhanced patient population using benralizumab
HK40008332A (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
HK1224583A1 (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
US20230348606A1 (en) Methods for treating severe asthma in patients with nasal polyposis
US20210095037A1 (en) Methods for treating late-onset asthma using benralizumab
Castro et al. TREATING INADEQUATELY CONTROLLED ASTHMA: EXPLORING THE POTENTIAL OF PHENOTYPE-TARGETED THERAPY

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ASTRAZENECA AB

Free format text: FORMER APPLICANT(S): MEDIMMUNE, LLC.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted